

# Milk, Dairy Products, and Their Functional Effects in Humans: A Narrative Review of Recent Evidence<sup>1</sup>

Francesco Visioli<sup>2\*</sup> and Andrea Strata<sup>3</sup>

<sup>2</sup>Laboratory of Functional Foods, Madrid Institute for Advanced Studies (IMDEA)–Food, CEI UAM+CSIC, Madrid, Spain; and <sup>3</sup>Department of Clinical Nutrition, University of Parma, Parma, Italy

## ABSTRACT

Milk is a widely consumed beverage that is essential to the diet of several millions of people worldwide because it provides important macro- and micronutrients. Milk is recognized as being useful during childhood and adolescence because of its composition; however, its relatively high saturated fat proportion raises issues of potential detrimental effects, namely on the cardiovascular system. This review evaluates the most recent literature on dairy and human health, framed within epidemiologic, experimental, and biochemical evidence. As an example, the effects of milk (notably skimmed milk) on body weight appear to be well documented, and the conclusions of the vast majority of published studies indicate that dairy consumption does not increase cardiovascular risk or the incidence of some cancers. Even though the available evidence is not conclusive, some studies suggest that milk and its derivatives might actually be beneficial to some population segments. Although future studies will help elucidate the role of milk and dairy products in human health, their use within a balanced diet should be considered in the absence of clear contraindications. *Adv. Nutr.* 5: 131–143, 2014.

## Introduction

Milk is an essential component of the diet of ~6 billion people. The world production of milk reaches 730 million tons/y (1,2). Even though mammals produce milk to feed their offspring, in many areas of the world humans continue to consume milk throughout their life. However, it must be emphasized that lactose intolerance is widespread throughout the world and that a large proportion of the world's population would not benefit from the putative benefits of milk.

In addition to milk, several dairy products such as cream, butter, yogurt, kefir, and cheese have been produced and consumed worldwide for millennia. Therefore, the impact of milk and dairy products on human health is quantitatively relevant and has been the subject of several investigations, on both whole products and their isolated components. In particular, the fat portion of milk (largely composed of SFAs) and some of its minor components, notably calcium and oligosaccharides, are being actively researched for their potential health roles.

This review summarizes the most recent studies on milk and human health and critically discusses the putative actions of milk and principal dairy constituents.

## Effects on Body Weight

Of all the bioactive milk components, calcium and vitamin D have been chiefly studied for their effects on body weight and adipose tissue. Studies have been performed on these compounds as either isolated molecules (3–9) or as components of milk and dairy products (5,7,8,10–12). Proposed targets include thermogenesis and lipid oxidation (which are enhanced by calcium and vitamin D) (13–15) and increased lipid fecal excretion (16–19).

In the past few years, some studies have been published on other milk components and their potential effects on body weight (20,21). For example, in addition to calcium and vitamin D, dairy proteins are being suggested as reducers of adipose mass (namely, visceral fat) and body weight (11,14,22,23). These effects have been observed in healthy participants as well as in overweight, obese (21,24–27), and diabetic (8,28) patients. In addition to casein, whey protein appears to be particularly effective (29,30), and their actions seem to be mediated by several mechanisms that include increased satiety and decreased appetite (29). In particular, inhibition of gastric secretion by cholecystokinin (31) and some branched amino acids, the abundance of leucine (32), increased secretion of glucagon-like peptide 1 (GLP-1)<sup>4</sup> (33,34) and glucose-dependent

<sup>1</sup> Author disclosures: F. Visioli and A. Strata, no conflicts of interest.

\* To whom correspondence should be addressed. E-mail: francesco.visioli/at/imdea.org.

<sup>4</sup> Abbreviations used: CVD, cardiovascular disease; GLP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; MCP-1, monocyte chemoattractant protein 1; MetS, metabolic syndrome.

insulinotropic polypeptide (GIP) (35), the concomitant suppression of ghrelin secretion (36), and the potent satiating effects of  $\alpha$ -lactalbumin (37) synergistically contribute to weight control.

The most recent studies in this area include randomized clinical trials and meta-analyses. A marked reduction in adipose tissue and an increase in lean mass were observed in 90 overweight and obese premenopausal women after 4 mo of a hypocaloric diet that included milk and dairy products. In particular, visceral adipose tissue was significantly affected (26). A study conducted in 903 healthy adolescents (15–16 y) that included at least 2 servings/d [1 serving = 200 mL of milk, 125 g of yogurt, or 28 g of cheese (38)] of dairy reported a significant weight loss and a reduction in body fat (39,40). Male participants also witnessed a protective effect on abdominal obesity. From a mechanistic viewpoint, whey protein administered before a meal exerted insulinotropic effects and reduced postprandial insulinemic fluctuations in healthy participants (41) and in type 2 diabetic patients (42). In the latter, consumption of whey protein before a high-glycemic-load (white bread and potatoes) breakfast or lunch increased insulin response by 30–50% and reduced glycemia by ~20%, compared with controls (42). This effect is quantitatively comparable to that of sulfonilureas (43). In agreement with these studies, Dove et al. (44) reported that the intake of 600 mL of skimmed milk at breakfast (by 34 overweight men and women) had a stronger satiating effect (evaluated 4 h later) than that of an isocaloric intake of fruit juice. A significantly lower consumption of foods offered ad libitum at lunch (i.e., after 4 h) was also recorded (44).

A recent meta-analysis (45) that reviewed the effect of 29 randomized clinical trials comprising 2101 cases confirmed the weight-loss effect of milk and dairy products when incorporated into hypocaloric diets. However, no beneficial effect of increasing dairy consumption on body weight and fat loss was seen in long-term studies or in studies without energy restriction, which calls for caution in attributing milk to slimming properties.

## Diabetes

A lower incidence of type 2 diabetes and of metabolic dysfunction associated with dairy consumption has been reported by observational studies (46), but the potential mechanisms responsible for these effects have not as yet been elucidated.

A prospective 10-y study in 37,185 women (i.e., the Women's Health Study) reported an inverse correlation between milk and dairy consumption and risk of diagnosed diabetes (28). This association was stronger for skimmed products and led to a 4% risk reduction for 1 additional serving/d. These effects can be hypothetically explained by increased insulinemic response, decreased glycemic fluctuations, and increased secretion of GIP and GLP-1 triggered by milk proteins, as described above, and by FAs such as *trans*-palmitoleic acid (*trans*-16:1n-7; see below) (47).

The Nurses' Health Study II (48) was carried out in 37,083 women, who were followed for 7 y. Every 2 y, women

receive a follow-up questionnaire with questions about diseases and health-related topics including pregnancy history, menopausal status, smoking habits, and hormone use. The first FFQ was collected in 1991 and subsequent FFQs are administered every 4 y. This study reported that dairy intake during high school was inversely associated with the risk of developing adult (self-reported) type 2 diabetes. In particular, 2 servings/d were associated with a 38% reduction in risk; the association was stronger when dairy consumption was continued throughout adulthood. A French prospective study (49) conducted in 3435 Parisians followed for 3 y observed that a higher intake of dairy products was associated with a lower incidence of (self-reported) type 2 diabetes, reduced glycemic tolerance, and metabolic syndrome (MetS). An inverse association (14% risk reduction) between milk consumption (especially skimmed or semi-skimmed milk) and type 2 diabetes has also been reported by Tong et al. (50), who published a meta-analysis of 7 cohort studies (328,029 cases). Another recent observational study in 82,076 postmenopausal women enrolled in the Women's Health Initiative Observational Study (which lasted for 8 y) confirmed that consumption of low-fat dairy products was significantly and inversely correlated with a reduced risk of (self-reported) type 2 diabetes, especially in high-BMI and obese women (51).

Mechanistically, a recent study (52) reported a marked amelioration of glycemic variables (i.e., fasting glycemia and hematic concentrations of glycated hemoglobin in type 2 diabetic patients who consumed fermented dairy and yogurt with added vitamin D, with or without calcium) (53). Finally, data from the EPIC (European Prospective Investigation into Cancer and Nutrition) study relative to 16,835 healthy and 12,403 diabetic participants (part of the larger 340,234 participant cohort) of 8 European nations confirmed the inverse association between cheese and fermented dairy consumption and incidence of diabetes. In particular, 55 g/d of cheese and yogurt were associated with a 12% reduction in type 2 diabetes incidence (54).

Finally, a recent study by Mozaffarian et al. (55) in 2617 adults enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA) confirmed the lower (–20%) incidence of type 2 diabetes associated with dairy use. This association was independent of sex, ethnicity, and other confounders and strengthens the notion that *trans*-palmitoleic acid might play important roles via its actions on insulin secretion, triglyceridemia, and blood pressure (see below). Indeed, the authors hypothesized that, when these beneficial actions are confirmed, dairy products could be enriched with this FA (55).

Interestingly, lactose, as opposed to glucose and fructose, intake does not appear to be associated with diabetes incidence (56,57). Even though the evidence in favor or against lactose use by diabetic patients is scant, the American Diabetes Association recommends the use of milk and dairy products. This is partly because milk has a relatively low glycemic index due to dairy proteins, in particular casein, which exhibit insulinogenic properties and facilitate

glycemic regulation through a mechanism involving elevation of certain plasma amino acids and stimulation of incretins (58). Finally, full-fat milk increases the mean gastric-emptying time compared with half-skimmed milk, and the low pH in fermented milk may delay gastric emptying. Therefore, full-fat or fermented milk might aid in glycemic control (59).

### Blood Pressure

Whey proteins have long been studied for their potentially positive effects on blood pressure (60,61). For example, Pal and Ellis (62) demonstrated that, in overweight and obese participants, the intake of 54 g/d of whey protein for 12 wk induced a significant reduction in both systolic and diastolic blood pressure, in agreement with Xu et al. (63) who published a meta-analysis of tripeptides and blood pressure. The former are bioactive peptides (64–66) that are formed from proteins via the actions of the microbiota and gastrointestinal enzymes and which are abundant in fermented dairy products (67). Tripeptides are being investigated because of their angiotensin-converting enzyme-inhibiting activities, which might have important clinical consequences. In particular, 2 tripeptides, namely isoleucine-proline-proline (Ile-Pro-Pro) and valine-proline-proline (Val-Pro-Pro) have been incorporated into functional foods because of their safety profile and purported beneficial activities, namely on blood pressure. It is noteworthy that, in addition to their activity on blood pressure, other peptides have been isolated and studied for their putative antithrombotic properties (68). Recently, McGrane et al. (69) reviewed the evidence of the hypotensive effects of milk tripeptides by updating a former 2010 review that 1) examined 223 articles published between 2004 and 2009 (which outlined the inverse association between milk tripeptide consumption and blood pressure) and 2) reviewed 163 studies published between July 2009 and December 2010 concerning vitamin D, calcium, phosphorus, and bioactive peptides in low-fat dairy as part of low-fat diets.

A meta-analysis of 7 studies that included ~45,000 participants, of whom 11,500 were hypertensive (70), reported a significantly inverse association between low-fat dairy consumption and hypertension risk. Nine other cohort studies (57,256 participants followed for 2–15 y) confirmed this inverse correlation; furthermore, those who consumed the highest quantity of low-fat dairy products exhibited the lowest risk of hypertension (71).

A prospective study recently published by Louie et al. (72), which analyzed 335 Australian children, their milk consumption at age 18 mo, and their blood pressure at 8 y of age, reported lower blood pressure values in those who consumed at least 2 servings/d.

### Cholesterol Concentrations

Milk and dairy products contain cholesterol (~80 mg/100 g) and saturated fat (~15 g/100 g) (73). Therefore, the intake of these products might theoretically have detrimental effects on cholesterol concentrations. However, it is noteworthy

that the contribution of dietary cholesterol to cardiovascular risk is being debated and might likely depend on individual predisposition to synthesize versus absorb cholesterol (74,75). Also, the extent and precise nature of the role of saturated fat in cardiovascular disease (CVD) onset and development are being reexamined (76); likely, SFAs cannot be grouped under a single rubric and should instead be considered individually (77).

The first review on the effects of dairy products on cholesterolemia was published in 2000 by St-Onge et al. (78). The authors cited as a first piece of evidence an old study carried out in the African Maasai ethnic group (79). Maasais consume large quantities of milk, which was inversely correlated with blood cholesterol concentrations in that study. Indeed, milk has even been proposed by the authors as an inhibitor of cholesterol synthesis. Further studies (80–82) confirmed the cholesterol-lowering effects of both milk and skimmed milk [which was already suggested by Hepner et al. (83)]. St-Onge et al. hypothesized that this effect was due to the intestinal microbial fermentation of indigestible carbohydrates, which would alter cholesterol synthesis and interfere with its enterohepatic circulation, in turn lowering cholesterolemia.

More recently, a study by Høstmark et al. (84) conducted in 18,770 participants examined the association between cheese consumption in various age groups and circulating concentrations of HDL cholesterol (which was positive) and TGs (which was negative). The authors attributed this effect to the FA composition of cheese and its bacterial content. The results led the authors to propose a revision of the current guidelines on SFA intake, namely that from cheese.

In terms of differential effects of the various dairy products, 1 study compared the effects of isoenergetic (20% of total calories, normalized for lactose and casein) provision of milk (2164 mL), cheese (305 g), and butter (93 g) administered in 3 different sessions during 3 wk (85). Cheese had the weakest effect on increasing LDL cholesterol, but whole milk increased concentrations of LDL cholesterol similar to butter. These results were confirmed by Biong et al. (86): the authors reported (in a controlled dietary study in 9 men and 13 women aged 23–54 y) that consumption of cheese induced a lower increase in cholesterol concentrations than that of an identical amount (42 g) of fat from butter. Different calcium content was proposed as a potential explanation for this differential effect. Nestel et al. (87) administered 40 g/d of either cheese or butter to 14 mildly hypercholesterolemic participants. Total and LDL cholesterol increased significantly after 4 wk in the butter group as compared with the cheese group. Tholstrup et al. (85) also questioned the current guidelines on saturated fat consumption and suggested the inclusion of modest amounts of cheese in the diets of mildly hypercholesterolemic participants. In agreement with this suggestion, Hjerpsted et al. (88) recently replaced 13% of total daily calories with 143 g of cheese or 47 g of butter (with the same lipid content) for 6 wk in a randomized crossover trial in 49 healthy participants. Their data showed that cheese did not increase LDL cholesterol

concentrations compared with the run-in period; rather, as compared with butter, it induced a significantly lower increase in total (5.7%) and LDL (6.9%) cholesterol.

Several potential explanations have been proposed to elucidate the differential effects of cheese and butter on cholesterolemia. One hypothesis is that calcium, the concentrations of which are higher in cheese than in butter, combines with FAs in the intestine and forms insoluble detergents as suggested by the observation of a higher-fat fecal excretion in the cheese compared with the butter groups (88). The higher protein and probiotic content of cheese could also speculatively contribute to its almost neutral effect on plasma cholesterol. As a cautionary note, the study by Tholstrup et al. (85) reported a lack of difference in the cholesterolemic effect of the diets containing whole milk and butter. In other words, as mentioned, whole milk did increase LDL-cholesterol concentrations similar to butter and its use by hypercholesterolemic patients should be considered with caution.

### MetS

Oxidative stress and inflammation play major roles in the onset and development of the MetS and its components (89–91). MetS diagnosis requires the presence of central obesity and at least 2 of the following 4 additional factors: high TGs, low HDL cholesterol, high blood pressure, or increased fasting plasma glucose concentration (92).

The Nurses' Health Study first reported an inverse association between a prudent diet that included low-fat dairy products and biomarkers of inflammation (93). Similar observations have been reported by the MESA (94) and prompted a series of investigations that explored mechanisms of actions and potential causation. Zemel et al. (95,96) supplemented 20 obese patients with skimmed milk for 28 d and recorded significantly lower oxidative stress (–22% of plasma malondialdehyde and –12% of 8-iso-PGF<sub>2α</sub> plasma concentrations) and inflammation [–15% TNF-α, –13% IL-6, –10% monocyte chemoattractant protein 1 (MCP-1), and +20% adiponectin]. The same authors (97) studied 40 obese MetS patients and showed that a 12-wk diet that included 3.5 servings/d of milk and/or yogurt reduced oxidative stress markers (–35% plasma malondialdehyde) after 7 d, as compared with an isocaloric diet that provided 0.5 servings/d of dairy products. After 12 wk, decreased systemic inflammation was also recorded in the dairy group (–35% TNF-α, –21% IL-6, +55% adiponectin), although not in the control arm.

The interesting observation that stems from these intervention studies is that the observed decrease in oxidative stress and inflammation markers was independent of body weight changes and became apparent shortly after the administration of dairy products, suggesting causation.

Epidemiologically, 1 recent Australian study reported an inverse association between MetS and type 2 diabetes incidence and dairy consumption in 1807 and 1824 patients, respectively. In particular, those who had the highest consumption amount of dairy products witnessed a risk reduction in MetS of

59% (72). A similar association was recorded when diabetes incidence was computed.

Finally, a recent meta-analysis (98) of 8 randomized controlled studies in overweight or obese participants concluded that dairy product consumption does not exert adverse effects on biomarkers of inflammation, even though further studies specifically designed to assess inflammation-related outcomes should be implemented (98).

### Cardiovascular Health

Several scientific societies and regulatory bodies (e.g., the International Society for the Study of Fatty Acids and Lipids, which is the foremost society; [www.issfal.org](http://www.issfal.org)), the FAO (99), and the European Food Safety Authority (100) recommend optimal profiles of FA intake. Even if no consensus has been reached and such guidelines are being constantly amended according to emerging evidence, some figures are being agreed upon. In particular, most societies concur with regard to adequate intakes (for adults) of >500 mg/d of long-chain omega-3 FAs and a concomitant limitation of <8% of energy from saturated fat.

More recently, a workshop entitled “Saturated fatty acids and cardiovascular disease prevention” (101) gathered several experts in the area of FAs and CVD, who reached the following consensus that also concerns milk and dairy FA profile:

1. Replacing saturated fat (SFAs) with PUFAs lowers cardiovascular risk. This effect is not seen when saturates are replaced with carbohydrates, especially those with a high glycemic index.
2. Even though replacing SFAs with MUFAs lowers LDL cholesterol, this effect does not translate into lower incidence of CVD.
3. LDL cholesterol is the most widely accepted risk factor for CVD; however, the HDL:LDL-cholesterol ratio is more predictive than the sole concentrations of LDL cholesterol.
4. Investigating the effects of dietary interventions on just 1 marker of CVD does not reliably predict clinical outcomes, because they depend on several rather than on just 1 factor.
5. The different SFAs exert varied biologic effects and have differential impact on cholesterolemia. As an example, myristic and palmitic acids are thought to be noxious, and stearic acid and short-to-medium-chain (C4–C10) FAs to be neutral; conjugated linoleic acid is so scarce in the diet that its metabolic effects are negligible.
6. Based on the epidemiologic studies published to date, there is no evidence to indicate that high intakes of dairy products increase CVD risk; conversely, the lipidic part of milk and its byproducts might be beneficial because of its peculiar FA profile, e.g., ruminic and vaccenic acids and the concomitant presence of calcium, whey proteins, and other bioactive molecules (101).

It should be noted that, after an initial report that proposed the “Alpine paradox” (102), considerable research is being undertaken to modulate the FA composition of bovine

milk toward a purportedly more healthful profile (103). In particular, milk from grass-fed livestock is being proposed as being more beneficial than that of corn-fed animals (104), although appropriate comparative human studies are lacking.

In 2002, Tavani et al. (105) published research carried out between 1995 and 1999 in 597 myocardial infarction patients, matched with 478 controls. Their data showed that milk and dairy consumption did not increase myocardial infarction risk. A meta-analysis of 21 studies that incorporated 347,747 participants followed for 5–23 y by Siri-Tarino et al. (106) reported no significant association between SFA consumption and increased risk of CVD or cerebrovascular diseases such as stroke. Further to this meta-analysis, the same authors (107) published an extensive review of the effects of various FAs on CVD risk. Their conclusion was that the replacement of SFAs with MUFAs and PUFAs reduces both LDL and HDL cholesterol. Moreover, substituting carbohydrates for SFAs increased CVD risk. Therefore, the most effective strategy to prevent CVD, based on this article, would be to reduce high-glycemic-index carbohydrates in obesity. In a study in 33,625 Dutch participants followed for 13 y, no association between dairy consumption and CVD or stroke incidence was observed; conversely, higher intakes were associated with lower CVD risk, whereas fermented milk products consumption was inversely associated with lower stroke risk (108).

As mentioned, the MetS is multifaceted and greatly increases CVD risk (109). In this respect, a review of observational studies concluded that milk and dairy consumption might contribute to cardiometabolic syndrome prevention; namely, 3–4 servings/d have been associated with cardiometabolic risk prevention (110). Consequently, based on current evidence, the most recent U.S. guidelines suggest to “Increase intake of fat-free or low-fat milk and milk products, such as milk, yogurt, cheese” (111).

In terms of mechanisms, Rice et al. (112) recently summarized the most prevalent hypothesis of how milk products would play preventive roles in cardiometabolism. These products mostly contain TGs with SFAs in the *sn*-2 position; in addition to high proportions of oleic and stearic acids, rumenic and *trans*-palmitoleic acids are also proportionally abundant. Moreover, part of the putative effects might be explained by the presence of several micronutrients such as calcium, vitamin D, whey proteins, and functional peptides (see above).

In terms of effects of milk FAs on CVD, there might be important differences between the individual FAs. A total of 5209 participants who had a daily intake of 10% of total energy from SFAs were followed for 10 y. Those whose proportional intake of SFAs from milk had a lower incidence of CVD compared with those who consumed an equivalent amount of SFAs from bovine meat. In particular, a 5-g/d increase in milk-derived SFAs was associated with a 21% decrease in CVD risk, whereas the same increase in meat-derived SFAs was associated with a 26% increase in CVD risk (113). As a cautionary note, the effects of FAs are

difficult to disentangle from those of other milk and meat components; therefore, more studies are needed to attribute potentially cardioprotective properties to milk FAs. A recent review by Huth and Park (114) concluded that the consumption of milk and dairy products cannot, as of today, be positively or negatively associated with cardiometabolic or stroke risk. Likewise, Kratz et al. (115) recently published a meta-analysis of 11 studies that concluded that the intake of high-fat dairy is inversely associated with the prevalence of obesity and (although modestly) with CVD and metabolic disorders. The conclusions of this article were that high-fat milk derivatives do not increase CVD risk and explain the diversified and heterogeneous outcomes of the studies they analyzed by the different animal feed (pasture vs. cereal-based feed), that would influence milk composition, as already observed by Jenkins et al. (116). This potential confounding factor should be added to other ones such as differences in lifestyle, background diets, etc. which results in overall disagreement over the precise role in CVD of milk and its products. One notable example of such disagreement can be found in Bonthuis et al. (117), who carried out a 16-y prospective study on 1529 Australian participants and concluded that the evidence in favor of a CVD-protective role of dairy products (an average of 339 g/d) was scant. Avalos et al. (118) also performed a 16-y prospective study in 751 men and 1008 women from San Diego, CA, and reported a multivariate analysis that showed how women who consumed the highest amounts of low-fat dairy exhibited higher CVD risk. One study, by Goldbohm et al. (119) analyzed 120,852 Dutch men and women (follow-up = 10 y) for their dairy product consumption as related to CVD. A neutral association was reported for men, and a slight increase in CVD mortality was recorded for women. Fermented dairy was associated with modest CVD protection in both sexes. Opposite results came from a recent study performed in Costa Rica in 3630 participants (120), in which dairy consumption was associated with myocardial infarction risk reduction, and from another, larger study in 36,636 Swedish women, followed for 11.6 y, that also reported an inverse association between milk and cheese consumption and myocardial infarction incidence, independent of fat content (121). These data are in agreement with those of Sonestedt et al. (122), who followed 26,445 participants of Malmö (Sweden) for 12 y and reported the following: 1) dairy consumption is inversely associated with CVD risk, 2) fermented milk use is significantly inversely associated with CVD risk, and 3) in women, cheese intake is significantly associated with CVD risk. Yet, a meta-analysis by Soedamah-Muthu et al. (123), who analyzed 17 prospective studies, came to the conclusion that milk consumption (200 mL/d) is modestly associated with lower CVD risk and that there is no correlation between the intake of milk and its derivatives and coronary disease or total mortality, regardless of their lipid content. Two subsequent studies reached the same conclusions. In the first (123), 4526 participants were followed for ~10 y; the results indicated an inverse association between fermented milk products use and total

mortality, yet not with diabetes or CVD incidence. The second study (52), in 5953 Danish participants aged 30–60 y who were followed for 5 y, reported a modest beneficial effect of cheese and fermented milk on glycemic control, yet not on type 2 diabetes incidence. Finally, a recent study (124) carried out in 1965 Dutch participants (follow-up = 12.4 y) did not report any association between cardiovascular and all-cause deaths and milk consumption. Moreover, the authors recorded an increased CVD risk associated with the use of high-fat foods. For every SD increase, the use of high-fat dairy products increased cardiovascular mortality by 36%.

A few years ago, the hypothesis was formulated that, in France, despite the presence of cardiovascular risk factors such as a high-fat diet, cardiovascular mortality was lower than that in neighboring countries (125). This apparent incongruence was attributed to the concomitant use of red wine, which is rich in phenolic compounds that act as antioxidants *in vitro*. Particular attention has been paid to resveratrol, to which several of the alleged healthy effects of wine have been attributed, even though very limited human data are available (126,127). Indeed, the hypothesis that the antioxidant and anti-inflammatory properties of nonalcoholic components might determine health effects different than that of ethanol is intriguing, but is, at present, only suggested by laboratory data and not by conclusive epidemiologic evidence (128,129).

In summary, the available evidence of an effect (whether beneficial or detrimental) of milk and dairy products on CVD is mixed and does not allow drawing firm conclusions. Even though milk and its derivatives are apparently able to positively modulate some risk factors and surrogate markers of cardiovascular health (e.g., insulin response, dyslipidemias, oxidative stress and inflammation markers, blood pressure, etc.), the net effect on CVD is as yet to be ascertained. Potential confounding factors such as fat content and FA profile, background diets, lifestyles, and coingestion of other beneficial or noxious dietary components likely contribute to this unclear picture. Future studies will add evidence to help resolve this issue.

### Cognitive Function

Cognitive function can be modulated, to some extent, by food (130), and its decline can be slowed down by adopting appropriate diet and lifestyle (131). Among all dietary components, relatively little attention has been paid to milk and its derivatives. Some studies reported amelioration of cognitive decline linked to augmentation of vascular function brought about by dairy consumption (132–134). However, specific studies have been performed only recently. A recent systematic review (135) identified 8 observational studies that reported a direct association between dairy consumption and better cognitive function. Crichton et al. (136) published a study in ~1000 Australian adults, in whom consumption of low-fat yogurt was positively associated with memory and socialization in men and low-fat cheese was associated positively with socialization and

negatively with stress in women. Conversely, regular-fat dairy was associated with increased stress, anxiety, cognitive decline, and worse memory. Of note, this study was performed by using questionnaires and not *ad hoc* tests. The same group (137) subsequently examined a subgroup of the Maine-Syracuse Longitudinal Study (which consisted of 5 cohorts defined by time of entry into the study, i.e., 1975–2000) and reported, by using neuropsychological tests, that milk use was associated in a dose-dependent fashion with better memory and slower cognitive decline. Quantification of these effects suggests 200 mL of milk/d as the lowest effective amount that, supposedly, would afford neuroprotection. In terms of cognitive development/performance, favorable effects on cognition and school performance were also observed in 469 students who were administered 250 mL/d of milk for 3 mo and who were evaluated by cognitive tests (138). Within the context of neuroprotection and cognitive decline, a recent interesting study by Birnie et al. (139) prospectively analyzed milk consumption during infancy and cognitive function later in life. The study started in 1930 by enrolling 5000 U.K. children and was concluded 65 y later by assessing the ambulation ability of 405 elderly participants. The data showed better (+5%) walking speed and balance (+25%) in those who consumed at least 1 glass of milk/d during their childhood.

### Chemoprevention

Milk contains compounds that might theoretically exert chemopreventive actions. In 1994, Kampman et al. (140) published an observational study in which 331 men and 350 women were followed for 4 and 8 y, respectively. No association between milk and fermented milk consumption and colorectal cancer was reported (141). Subsequent studies provided mixed results: although some researchers found positive associations between dairy use and prostate (142–145) and ovary (146) cancers, others found the opposite when colorectal (147), lung (148,149), or breast (150) cancers were investigated. What is possibly the largest prospective cohort study in this field was published in 2009 by Park et al. (151), who analyzed, via the use of a questionnaire, diets and cancer incidence in 293,907 men and 198,903 women, with a follow-up of 7 y. Their data showed that calcium and dairy intake was inversely associated with gastrointestinal (especially colorectal) cancer incidence. The multivariate analysis showed a calcium-associated reduction in gastrointestinal cancer risk of 16% for men and 23% for women. Other cancers were also inversely associated with milk and cheese intake, namely those of the head and neck, esophagus, stomach, colon, and bladder. This putatively protective effect of dairy intake has been ascribed to the milk content of potentially chemopreventive compounds such as calcium, vitamin D, conjugated linoleic acid, etc. (152). In particular, calcium has been suggested to inhibit cell proliferation, stimulate differentiation and apoptosis in the gastrointestinal tract and in the mammalian gland, and bind to FAs and biliary salts in the intestine, therefore lessening their potentially noxious effects on the

mucosa. However, calcium would also interact with vitamin D and with insulin-like growth factor 1, in turn increasing the risk of prostate cancer (142,153). Indeed, Park et al. (151) did report increased prostate cancer risk linked to higher dairy and calcium consumption. In 2 European studies (154,155), the inverse association between milk use and colorectal cancer was confirmed. In the first study (154), 45,241 participants were followed for 12 y and their intake of yogurt was monitored (mean: 85 g/d for men and 98 g/d for women) and plotted against colorectal cancer incidence, showing an inverse association that was stronger in men. A systematic review by Aune et al. (155) took into account 19 cohort studies and reported a significantly inverse association between milk (200 mL/d) and total dairy (400 g/d), yet not cheese (50 g/d), consumption and colorectal cancer incidence.

With regard to breast cancer, after the first report by Knekt et al. (156) of a significantly inverse association between milk use and breast cancer incidence in 4697 Finnish women, Shin et al. (157) published a cohort study in which they did not find any association between dairy, calcium, or vitamin D consumption and breast cancer incidence in postmenopausal women. Conversely, in premenopausal women, a significant reduction in breast cancer risk associated with low-fat dairy products was reported. Of note, a subsequent meta-analysis (158) of >20 studies (that included a total of 351,041 women with a follow-up of 15 y) did not find any association between these 2 variables. In agreement with these data, a successive review (150) did not find convincing evidence that milk consumption is associated with lower breast cancer incidence. Conversely, Dong et al. (159) conducted a meta-analysis in 1,063,471 participants in 18 prospective cohort studies and reported an inverse association between dairy, although not milk, use and breast cancer, notably in premenopausal women and when low-fat products were separately analyzed (160,161). In summary, there is no evidence that milk and dairy use increases or reduces the incidence of breast cancer.

A similar picture is shown with milk and bladder cancer. One meta-analysis by Mao et al. (162) (who analyzed 19 cohort case-control studies totaling 7867 bladder cancer patients) reported that high milk consumption was associated with a 16% reduction in bladder cancer risk; this inverse association was stronger in Asian participants than in North American participants and was not seen in Europeans. Finally, the statistical significance depended on the type of dairy product that was analyzed. Another meta-analysis (163) examined 14 studies on milk (4879 cases of bladder cancer) and 6 studies on dairy products (3087 cases) conducted in a total of 324,241 participants. No correlations between variables were found.

With regard to other cancers, no clear evidence emerges from most of the studies that have been published thus far, including lung (149), ovary (146), esophagus and stomach (164–166), and oropharyngeal (167,168) cancers. Positive associations between dairy use and prostate cancers have been published, and several mechanisms of action

have been proposed to explain this hypothetical effect (142–144,169,170). The lay public is familiar with the “China Study” (which was actually a book rather than a peer-reviewed article), which concluded that animal protein, namely casein given to laboratory animals, provoked tumors such as prostate cancer. On the basis of current evidence, the effects of casein—particularly isolated casein, separated from other components of dairy that often work synergistically—cannot be generalized to all forms of milk protein, much less all forms of animal protein. In fact, experiments in rodents suggest some antitumor activity of dairy protein fraction and, more specifically, of the whey protein component of milk because of its glutathione-increasing effects (171). In short, even though a cancer-promoting effect of casein and other milk proteins cannot be ruled out, the evidence in favor or against such effect is still too limited to draw firm conclusions.

### **Milk Components with Putative Functional Properties**

Recently, several oligosaccharides have been categorized in milk and have been suggested as potentially bioactive ingredients. Even though bovine milk contains only trace amounts of these beneficial components (172), some researchers are working toward producing human milk oligosaccharides in transgenic animals (173). Due to the lack of suitable commercial standards for bovine oligosaccharides, we can only identify >70 fully annotated oligosaccharides in human milk and ~40 in bovine milk, of which 24 contain sialic acid (172). Oligosaccharides are composed of a lactose core bound to lactose-amine units via  $\beta$ 1–3 or  $\beta$ 1–6 links and carrying fucose or sialic acid in their terminal position (172,174,175). It is noteworthy that these molecules are abundant in human milk and have been proposed as important for child development. Neutral oligosaccharides—namely the monomer *N*-acetylglucosamine and fucose—are essential to the development of the microbiota of breast-fed neonates because of their immunomodulating actions (176). Conversely, acidic oligosaccharides (where the monomer is sialic acid) help to prevent the adhesion of pathogens to the intestinal mucosa (177). Bovine milk also contains these oligosaccharides, which are abundant in colostrum (178,179). Oligosaccharides are prebiotics and help to create a healthy microbiota (180–182). Even though a thorough discussion on the role of the microbiota in human health goes beyond the aim of this article, this is an important and dynamic field of research that is attracting considerable attention and is being addressed from several viewpoints (183–185). Even though many fruits and vegetables contain oligosaccharides and some of them have been synthesized, those from milk are remarkable in that they exhibit a branched rather than a linear structure. Moreover, they contain fucose and sialic acid, which are almost absent in other oligosaccharides. This structural difference might confirm that milk oligosaccharide activities are different than oligosaccharides of synthetic or vegetal origin. It must be underscored that the concentration of oligosaccharides in bovine milk decreases

in a time-dependent fashion: ad hoc investigations are being carried out to formulate these compounds as nutraceuticals or as probiotic components of functional foods (172).

Finally, it is noteworthy that some kinds of cheeses, namely those infected with *Penicillium* such as Roquefort, Stilton, or Gorgonzola, exhibit high concentrations of andrastins A–D, which are potent inhibitors of farnesyltransferase, a key enzyme in cholesterol synthesis (186). Other peptides formed during ripening-induced proteolysis might further contribute healthful, albeit as yet unexplored, properties that would partially explain the relatively low incidence of CVD in high-cheese-consumption countries.

Milk is also often fortified, e.g., with vitamin D or omega-3 FAs (187), because it provides an excellent vehicle for fat-soluble molecules (see below) and can be marketed to target population groups after appropriate regulatory evaluation (188). In summary, either fortified or “natural” milk and dairy products contain several compounds—even though they are often present in low concentrations—that might in the future be exploited for pharma-nutrition applications (189).

## Conclusions

Milk and its derivatives are proposed as being useful foods throughout all life periods, in particular during childhood and adolescence, when their contents of calcium, protein, phosphorus, and other micronutrients might promote skeletal, muscular, and neurologic development. However, their relatively high saturated fat proportion [milk fat contains ~70% SFAs; myristic and palmitic acids combined account for ~50% (190), whereas the remainder are mostly short- and medium-chain FAs and oleic acid (191,192)] has flagged them as potentially detrimental food items, especially in terms of cardiovascular health. The recent literature reviewed in this article helps shed some light on the role of milk in a balanced diet. The vast majority of epidemiologic and intervention studies performed during the past few years suggest that dairy products do not adversely affect surrogate markers of CVD and cardiovascular prognosis. Indeed, some studies suggest that SFAs, namely, shorter-chain SFAs, from milk and its derivatives are benign with regard to inflammation (193) and might actually be beneficial to some population segments (193). The available evidence suggests that calcium does not play a major role in coronary calcification (194) [at least from an epidemiologic viewpoint: randomized clinical trials are inconclusive (195)] and its intake is inversely associated with blood pressure, whereas its potential contribution to prostate cancer development is still controversial (196). Therefore, the hypothesized association between calcium intake and cardiovascular risk is not currently supported by scientific evidence, and, in fact, the reverse might be true. In addition, some milk components such as *trans* fatty acids [which might have different physiologic actions than the industrial ones (197,198)], butyric acid [which might be helpful for the intestinal mucosa's trophism (199)], conjugated linoleic acid [even though the jury is still out as

far as its putative health effects are concerned, there are efforts to increase its concentrations in bovine milk (103)], phospholipids (200), tripeptides, calcium, phosphorus, lactoferrin (201), and oligosaccharides might exert useful, although as yet unproven, physiologic actions. Furthermore, milk has been shown to be an efficient vehicle for lipid-soluble nutrient absorption (187) because milk fat appears to be highly dispersed in very small micelles (202).

In conclusion, whereas future studies will help to elucidate the role of milk and dairy products in human health, their use within a balanced diet should be considered in the absence of clear contraindications.

## Acknowledgments

Both authors read and approved the final version of the manuscript.

## Literature Cited

1. Hemme T, Otte J. Status of and prospects for smallholder milk production—a global perspective. Rome: FAO; 2010.
2. FAO. Food outlook—global market analysis. Rome: FAO; 2012.
3. Davies KM, Heaney RP, Recker RR, Lappe JM, Barger-Lux MJ, Rafferty K, Hinders S. Calcium intake and body weight. *J Clin Endocrinol Metab.* 2000;85:4635–8.
4. Parikh SJ, Yanovski JA. Calcium intake and adiposity. *Am J Clin Nutr.* 2003;77:281–7.
5. Major GC, Alarie F, Dore J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. *Am J Clin Nutr.* 2007;85:54–9.
6. Pereira MA, Jacobs DR Jr, Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA study. *JAMA.* 2002;287:2081–9.
7. Zemel MB, Shi H, Greer B, Dirienzo D, Zemel PC. Regulation of adiposity by dietary calcium. *FASEB J.* 2000;14:1132–8.
8. Shahar DR, Abel R, Elhayany A, Vardi H, Fraser D. Does dairy calcium intake enhance weight loss among overweight diabetic patients? *Diabetes Care.* 2007;30:485–9.
9. Shahar DR, Schwarzfuchs D, Fraser D, Vardi H, Thiery J, Fiedler GM, Bluhner M, Stumvoll M, Stampfer MJ, Shai I. Dairy calcium intake, serum vitamin D, and successful weight loss. *Am J Clin Nutr.* 2010;92:1017–22.
10. Zemel MB. Role of dietary calcium and dairy products in modulating adiposity. *Lipids.* 2003;38:139–46.
11. Zemel MB, Richards J, Mathis S, Milstead A, Gebhardt L, Silva E. Dairy augmentation of total and central fat loss in obese subjects. *Int J Obes (Lond).* 2005;29:391–7.
12. Zemel MB, Thompson W, Milstead A, Morris K, Campbell P. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. *Obes Res.* 2004;12:582–90.
13. Melanson EL, Sharp TA, Schneider J, Donahoo WT, Grunwald GK, Hill JO. Relation between calcium intake and fat oxidation in adult humans. *Int J Obes Relat Metab Disord.* 2003;27:196–203.
14. Teegarden D. The influence of dairy product consumption on body composition. *J Nutr.* 2005;135:2749–52.
15. Teegarden D, White KM, Lyle RM, Zemel MB, Van Loan MD, Matkovic V, Craig BA, Schoeller DA. Calcium and dairy product modulation of lipid utilization and energy expenditure. *Obesity (Silver Spring).* 2008;16:1566–72.
16. Van der Meer R, Welberg JW, Kuipers F, Kleibeuker JH, Mulder NH, Termont DS, Vonk RJ, De Vries HT, De Vries EG. Effects of supplemental dietary calcium on the intestinal association of calcium, phosphate, and bile acids. *Gastroenterology.* 1990;99:1653–9.



17. Denke MA, Fox MM, Schulte MC. Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men. *J Nutr.* 1993;123:1047–53.
18. Astrup A, Chaput JP, Gilbert JA, Lorenzen JK. Dairy beverages and energy balance. *Physiol Behav.* 2010;100:67–75.
19. Christensen R, Lorenzen JK, Svith CR, Bartels EM, Melanson EL, Saris WH, Tremblay A, Astrup A. Effect of calcium from dairy and dietary supplements on faecal fat excretion: a meta-analysis of randomized controlled trials. *Obes Rev.* 2009;10:475–86.
20. Van Loan M. The role of dairy foods and dietary calcium in weight management. *J Am Coll Nutr.* 2009;28 Suppl 1:120S–9S.
21. Sanders TA. Role of dairy foods in weight management. *Am J Clin Nutr.* 2012;96:687–8.
22. Vergnaud AC, Peneau S, Chat-Yung S, Kesse E, Czernichow S, Galan P, Hercberg S, Bertrais S. Dairy consumption and 6-y changes in body weight and waist circumference in middle-aged French adults. *Am J Clin Nutr.* 2008;88:1248–55.
23. Mirmiran P, Esmailzadeh A, Azizi F. Dairy consumption and body mass index: an inverse relationship. *Int J Obes (Lond).* 2005;29:115–21.
24. Faghhih S, Abadi AR, Hedayati M, Kimiagar SM. Comparison of the effects of cows' milk, fortified soy milk, and calcium supplement on weight and fat loss in premenopausal overweight and obese women. *Nutr Metab Cardiovasc Dis.* 2011;21:499–503.
25. Rosell M, Hakansson NN, Wolk A. Association between dairy food consumption and weight change over 9 y in 19,352 perimenopausal women. *Am J Clin Nutr.* 2006;84:1481–8.
26. Josse AR, Atkinson SA, Tarnopolsky MA, Phillips SM. Increased consumption of dairy foods and protein during diet- and exercise-induced weight loss promotes fat mass loss and lean mass gain in overweight and obese premenopausal women. *J Nutr.* 2011;141:1626–34.
27. Abargouei AS, Janghorbani M, Salehi-Marzjari M, Esmailzadeh A. Effect of dairy consumption on weight and body composition in adults: a systematic review and meta-analysis of randomized controlled clinical trials. *Int J Obes (Lond).* 2012;36:1485–93.
28. Liu S, Choi HK, Ford E, Song Y, Klevak A, Buring JE, Manson JE. A prospective study of dairy intake and the risk of type 2 diabetes in women. *Diabetes Care.* 2006;29:1579–84.
29. Sousa GT, Lira FS, Rosa JC, de Oliveira EP, Oyama LM, Santos RV, Pimentel GD. Dietary whey protein lessens several risk factors for metabolic diseases: a review. *Lipids Health Dis.* 2012;11:67.
30. Pal S, Ellis V, Dhaliwal S. Effects of whey protein isolate on body composition, lipids, insulin and glucose in overweight and obese individuals. *Br J Nutr.* 2010;104:716–23.
31. Strader AD, Woods SC. Gastrointestinal hormones and food intake. *Gastroenterology.* 2005;128:175–91.
32. Layman DK, Walker DA. Potential importance of leucine in treatment of obesity and the metabolic syndrome. *J Nutr.* 2006;136:319S–23S.
33. Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. *Can J Physiol Pharmacol.* 2003;81:1005–12.
34. Hall WL, Millward DJ, Long SJ, Morgan LM. Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. *Br J Nutr.* 2003;89:239–48.
35. Samra RA, Wolever TM, Anderson GH. Enhanced food intake regulatory responses after a glucose drink in hyperinsulinemic men. *Int J Obes (Lond).* 2007;31:1222–31.
36. Bowen J, Noakes M, Trenerry C, Clifton PM. Energy intake, ghrelin, and cholecystokinin after different carbohydrate and protein preloads in overweight men. *J Clin Endocrinol Metab.* 2006;91:1477–83.
37. Nieuwenhuizen AG, Hochstenbach-Waelen A, Veldhorst MA, Westerterp KR, Engelen MP, Brummer RJ, Deutz NE, Westerterp-Plantenga MS. Acute effects of breakfasts containing alpha-lactalbumin, or gelatin with or without added tryptophan, on hunger, 'satiety' hormones and amino acid profiles. *Br J Nutr.* 2009;101:1859–66.
38. Scientific substantiation of a health claim related to dairy foods and healthy body weight pursuant to article 14 of regulation (EC) no 1924/2006. EFSA J. 2008;786:1–9.
39. Abreu S, Santos R, Moreira C, Vale S, Santos PC, Soares-Miranda L, Marques AI, Mota J, Moreira P. Association between dairy product intake and abdominal obesity in Azorean adolescents. *Eur J Clin Nutr.* 2012;66:830–5.
40. Abreu S, Santos R, Moreira C, Santos PC, Vale S, Soares-Miranda L, Mota J, Moreira P. Milk intake is inversely related to body mass index and body fat in girls. *Eur J Pediatr.* 2012;171:1467–74.
41. Akhavan T, Lubovyy BL, Brown PH, Cho CE, Anderson GH. Effect of premeal consumption of whey protein and its hydrolysate on food intake and postmeal glycemia and insulin responses in young adults. *Am J Clin Nutr.* 2010;91:966–75.
42. Frid AH, Nilsson M, Holst JJ, Bjorck IM. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. *Am J Clin Nutr.* 2005;82:69–75.
43. Ma J, Stevens JE, Cukier K, Maddox AF, Wishart JM, Jones KL, Clifton PM, Horowitz M, Rayner CK. Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. *Diabetes Care.* 2009;32:1600–2.
44. Dove ER, Hodgson JM, Puddey IB, Beilin LJ, Lee YP, Mori TA. Skim milk compared with a fruit drink acutely reduces appetite and energy intake in overweight men and women. *Am J Clin Nutr.* 2009;90:70–5.
45. Chen M, Pan A, Malik VS, Hu FB. Effects of dairy intake on body weight and fat: a meta-analysis of randomized controlled trials. *Am J Clin Nutr.* 2012;96:735–47.
46. Choi HK, Willett WC, Stampfer MJ, Rimm E, Hu FB. Dairy consumption and risk of type 2 diabetes mellitus in men: a prospective study. *Arch Intern Med.* 2005;165:997–1003.
47. Mozaffarian D, Cao H, King IB, Lemaitre RN, Song X, Siscovick DS, Hotamisligil GS. Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. *Ann Intern Med.* 2010;153:790–9.
48. Malik VS, Sun Q, van Dam RM, Rimm EB, Willett WC, Rosner B, Hu FB. Adolescent dairy product consumption and risk of type 2 diabetes in middle-aged women. *Am J Clin Nutr.* 2011;94:854–61.
49. Fumeron F, Lamri A, Abi Khalil C, Jaziri R, Porchay-Balderelli I, Lantieri O, Vol S, Balkau B, Marre M. Dairy consumption and the incidence of hyperglycemia and the metabolic syndrome: results from a French prospective study, data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). *Diabetes Care.* 2011;34:813–7.
50. Tong X, Dong JY, Wu ZW, Li W, Qin LQ. Dairy consumption and risk of type 2 diabetes mellitus: a meta-analysis of cohort studies. *Eur J Clin Nutr.* 2011;65:1027–31.
51. Margolis KL, Wei F, de Boer IH, Howard BV, Liu S, Manson JE, Mossavar-Rahmani Y, Phillips LS, Shikany JM, Tinker LF. A diet high in low-fat dairy products lowers diabetes risk in postmenopausal women. *J Nutr.* 2011;141:1969–74.
52. Struijk EA, Heraclides A, Witte DR, Soedamah-Muthu SS, Geleijnse JM, Toft U, Lau CJ. Dairy product intake in relation to glucose regulation indices and risk of type 2 diabetes. *Nutr Metab Cardiovasc Dis.* 2013;23:822–8.
53. Nikooyeh B, Neyestani TR, Farvid M, Alavi-Majd H, Houshiarrad A, Kalayi A, Shariatzadeh N, Gharavi A, Heravifard S, Tayebinejad N, et al. Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial. *Am J Clin Nutr.* 2011;93:764–71.
54. Sluijjs I, Forouhi NG, Beulens JW, van der Schouw YT, Agnoli C, Arriola L, Balkau B, Barricarte A, Boeing H, Bueno-de-Mesquita HB, et al. The amount and type of dairy product intake and incident type 2 diabetes: results from the EPIC-Interact study. *Am J Clin Nutr.* 2012;96:382–90.
55. Mozaffarian D, de Oliveira Otto MC, Lemaitre RN, Fretts AM, Hotamisligil G, Tsai MY, Siscovick DS, Nettleton JA. Trans-palmitoleic acid, other dairy fat biomarkers, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Clin Nutr.* 2013;97:854–61.
56. Ahmadi-Abhari S, Luben RN, Powell N, Bhaniani A, Chowdhury R, Wareham NJ, Forouhi NG, Khaw KT. Dietary intake of carbohydrates

- and risk of type 2 diabetes: the European Prospective Investigation into Cancer–Norfolk Study. *Br J Nutr*. 2013;23:1–11.
57. Jaffiol C. [Milk and dairy products in the prevention and therapy of obesity, type 2 diabetes and metabolic syndrome.] *Bull Acad Natl Med*. 2008;192:749–58.
  58. Gunnerud U, Holst JJ, Ostman E, Bjorck I. The glycemic, insulinemic and plasma amino acid responses to equi-carbohydrate milk meals, a pilot-study of bovine and human milk. *Nutr J*. 2012;11:83.
  59. Haug A, Hostmark AT, Harstad OM. Bovine milk in human nutrition—a review. *Lipids Health Dis*. 2007;6:25.
  60. Sánchez D, Kassam M, Contreras Mdel M, Carron R, Recio I, Montero MJ, Sevilla MA. Long-term intake of a milk casein hydrolysate attenuates the development of hypertension and involves cardiovascular benefits. *Pharmacol Res*. 2011;63:398–404.
  61. Meisel H. Biochemical properties of peptides encrypted in bovine milk proteins. *Curr Med Chem*. 2005;12:1905–19.
  62. Pal S, Ellis V. The chronic effects of whey proteins on blood pressure, vascular function, and inflammatory markers in overweight individuals. *Obesity (Silver Spring)*. 2010;18:1354–9.
  63. Xu JY, Qin LQ, Wang PY, Li W, Chang C. Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. *Nutrition*. 2008;24:933–40.
  64. Boelsma E, Kloek J. Lactotripeptides and antihypertensive effects: a critical review. *Br J Nutr*. 2009;101:776–86.
  65. Geleijnse JM, Engberink MF. Lactopeptides and human blood pressure. *Curr Opin Lipidol*. 2010;21:58–63.
  66. Meisel H. Multifunctional peptides encrypted in milk proteins. *Biofactors*. 2004;21:55–61.
  67. Choi J, Sabikhi L, Hassan A, Anand S. Bioactive peptides in dairy products. *Int J Dairy Technol*. 2012;65:1–12.
  68. Phelan M, Kerins D. The potential role of milk-derived peptides in cardiovascular disease. *Food Funct*. 2011;2:153–67.
  69. McGrane MM, Essery E, Obbagy J, Lyon J, Macneil P, Spahn J, Van Horn L. Dairy consumption, blood pressure, and risk of hypertension: an evidence-based review of recent literature. *Curr Cardiovasc Risk Rep*. 2011;5:287–98.
  70. Ralston RA, Lee JH, Truby H, Palermo CE, Walker KZ. A systematic review and meta-analysis of elevated blood pressure and consumption of dairy foods. *J Hum Hypertens*. 2012;26:3–13.
  71. Soedamah-Muthu SS, Verberne LD, Ding EL, Engberink MF, Geleijnse JM. Dairy consumption and incidence of hypertension: a dose-response meta-analysis of prospective cohort studies. *Hypertension*. 2012;60:1131–7.
  72. Louie JC, Flood VM, Rangan AM, Burlutsky G, Gill TP, Gopinath B, Mitchell P. Higher regular fat dairy consumption is associated with lower incidence of metabolic syndrome but not type 2 diabetes. *Nutr Metab Cardiovasc Dis*. 2013;23:816–21.
  73. Agricultural Research Service, USDA. National Nutrient Database for Standard Reference. Release 26 [cited 2013 Nov 23]. Available from: <http://ndb.Nal.USda.Gov/ndb/foods/show/26?Qlookup=01026&max=25&man=&facet=&new=1>.
  74. Fernandez ML, Calle M. Revisiting dietary cholesterol recommendations: does the evidence support a limit of 300 mg/d? *Curr Atheroscler Rep*. 2010;12:377–83.
  75. Rong Y, Chen L, Zhu T, Song Y, Yu M, Shan Z, Sands A, Hu FB, Liu L. Egg consumption and risk of coronary heart disease and stroke: Dose-response meta-analysis of prospective cohort studies. *BMJ*. 2013;346:e8539.
  76. Micha R, Mozaffarian D. Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence. *Lipids*. 2010;45:893–905.
  77. Legrand P, Rioux V. The complex and important cellular and metabolic functions of saturated fatty acids. *Lipids*. 2010;45:941–6.
  78. St-Onge MP, Farnworth ER, Jones PJ. Consumption of fermented and nonfermented dairy products: effects on cholesterol concentrations and metabolism. *Am J Clin Nutr*. 2000;71:674–81.
  79. Mann GV, Spoerri A. Studies of a surfactant and cholesterolemia in the Maasai. *Am J Clin Nutr*. 1974;27:464–9.
  80. Steinmetz KA, Childs MT, Stimson C, Kushi LH, McGovern PG, Potter JD, Yamanaka WK. Effect of consumption of whole milk and skim milk on blood lipid profiles in healthy men. *Am J Clin Nutr*. 1994;59:612–8.
  81. Sharpe SJ, Gamble GD, Sharpe DN. Cholesterol-lowering and blood pressure effects of immune milk. *Am J Clin Nutr*. 1994;59:929–34.
  82. Buonopane GJ, Kilara A, Smith JS, McCarthy RD. Effect of skim milk supplementation on blood cholesterol concentration, blood pressure, and triglycerides in a free-living human population. *J Am Coll Nutr*. 1992;11:56–67.
  83. Hepner G, Fried R, St Jeor S, Fusetti L, Morin R. Hypocholesterolemic effect of yogurt and milk. *Am J Clin Nutr*. 1979;32:19–24.
  84. Hostmark AT, Haug A, Tomten SE, Thelle DS, Mosdøl A. Serum HDL cholesterol was positively associated with cheese intake in the Oslo Health Study. *J Food Lipids*. 2009;16:89–102.
  85. Tholstrup T, Hoy CE, Andersen LN, Christensen RD, Sandstrom B. Does fat in milk, butter and cheese affect blood lipids and cholesterol differently? *J Am Coll Nutr*. 2004;23:169–76.
  86. Biong AS, Muller H, Seljeflot I, Veierod MB, Pedersen JI. A comparison of the effects of cheese and butter on serum lipids, haemostatic variables and homocysteine. *Br J Nutr*. 2004;92:791–7.
  87. Nestel PJ, Chronopoulos A, Cehun M. Dairy fat in cheese raises LDL cholesterol less than that in butter in mildly hypercholesterolaemic subjects. *Eur J Clin Nutr*. 2005;59:1059–63.
  88. Hjerpsted J, Leedo E, Tholstrup T. Cheese intake in large amounts lowers LDL-cholesterol concentrations compared with butter intake of equal fat content. *Am J Clin Nutr*. 2011;94:1479–84.
  89. Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. *Obesity (Silver Spring)*. 2006;14:2127–31.
  90. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. *J Clin Invest*. 2004;114:1752–61.
  91. Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. *Int J Obes Relat Metab Disord*. 2001;25:1407–15.
  92. Visioli F. Nutritional support in the pharmacological treatment of metabolic syndrome. *Eur J Pharmacol*. 2011;668 Suppl 1:S43–9.
  93. Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, Hu FB. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. *Am J Clin Nutr*. 2004;80:1029–35.
  94. Nettleton JA, Steffen LM, Mayer-Davis EJ, Jenny NS, Jiang R, Herrington DM, Jacobs DR Jr. Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Clin Nutr*. 2006;83:1369–79.
  95. Zemel MB. Proposed role of calcium and dairy food components in weight management and metabolic health. *Phys Sportsmed*. 2009;37:29–39.
  96. Zemel MB, Sun X, Sobhani T, Wilson B. Effects of dairy compared with soy on oxidative and inflammatory stress in overweight and obese subjects. *Am J Clin Nutr*. 2010;91:16–22.
  97. Stancliffe RA, Thorpe T, Zemel MB. Dairy attenuates oxidative and inflammatory stress in metabolic syndrome. *Am J Clin Nutr*. 2011;94:422–30.
  98. Labonté ME, Couture P, Richard C, Desroches S, Lamarche B. Impact of dairy products on biomarkers of inflammation: a systematic review of randomized controlled nutritional intervention studies in overweight and obese adults. *Am J Clin Nutr*. 2013;97:706–17.
  99. FAO. Fats and fatty acids in human nutrition: report of an expert consultation. Rome: FAO; 2010.
  100. European Food Safety Authority. Scientific opinion on dietary reference values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol EFSA J. 2010;8:1471–1578.

101. Astrup A, Dyerberg J, Elwood P, Hermansen K, Hu FB, Jakobsen MU, Kok FJ, Krauss RM, Lecerf JM, LeGrand P, et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? *Am J Clin Nutr.* 2011;93:684–8.
102. Hauswirth CB, Scheeder MR, Beer JH. High omega-3 fatty acid content in alpine cheese: the basis for an alpine paradox. *Circulation.* 2004;109:103–7.
103. Shingfield KJ, Bonnet M, Scollan ND. Recent developments in altering the fatty acid composition of ruminant-derived foods. *Anim* 2013;7 Suppl 1:132–62.
104. Leiber F, Kreuzer M, Nigg D, Wettstein HR, Scheeder MR. A study on the causes for the elevated n-3 fatty acids in cows' milk of alpine origin. *Lipids.* 2005;40:191–202.
105. Tavani A, Gallus S, Negri E, La Vecchia C. Milk, dairy products, and coronary heart disease. *J Epidemiol Community Health.* 2002;56:471–2.
106. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. *Am J Clin Nutr.* 2010;91:535–46.
107. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fatty acids and risk of coronary heart disease: modulation by replacement nutrients. *Curr Atheroscler Rep.* 2010;12:384–90.
108. Dalmeijer GW, Struijk EA, van der Schouw YT, Soedamah-Muthu SS, Verschuren WM, Boer JM, Geleijnse JM, Beulens JW. Dairy intake and coronary heart disease or stroke—a population-based cohort study. *Int J Cardiol.* 2013;167:925–9.
109. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. *Natl Health Stat Rep.* 2009:1–7.
110. Tremblay A, Gilbert JA. Milk products, insulin resistance syndrome and type 2 diabetes. *J Am Coll Nutr.* 2009;28 Suppl 1:91S–102S.
111. USDA. Report of the Dietary Guidelines Advisory Committee on the Dietary Guidelines for Americans 2010 to the Secretary of Health and Human Services and the Secretary of Agriculture. Washington: USDA; 2010.
112. Rice BH, Quann EE, Miller GD. Meeting and exceeding dairy recommendations: effects of dairy consumption on nutrient intakes and risk of chronic disease. *Nutr Rev.* 2013;71:209–23.
113. de Oliveira Otto MC, Mozaffarian D, Kromhout D, Bertoni AG, Sibley CT, Jacobs DR Jr, Nettleton JA. Dietary intake of saturated fat by food source and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. *Am J Clin Nutr.* 2012;96:397–404.
114. Huth PJ, Park KM. Influence of dairy product and milk fat consumption on cardiovascular disease risk: a review of the evidence. *Adv Nutr.* 2012;3:266–85.
115. Kratz M, Baars T, Guyenet S. The relationship between high-fat dairy consumption and obesity, cardiovascular, and metabolic disease. *Eur J Nutr.* 2013;52:1–24.
116. Jenkins TC, McGuire MA. Major advances in nutrition: impact on milk composition. *J Dairy Sci.* 2006;89:1302–10.
117. Bonthuis M, Hughes MC, Ibiebele TI, Green AC, van der Pols JC. Dairy consumption and patterns of mortality of Australian adults. *Eur J Clin Nutr.* 2010;64:569–77.
118. Avalos EE, Barrett-Connor E, Krititz-Silverstein D, Wingard DL, Bergstrom JN, Al-Delaimy WK. Is dairy product consumption associated with the incidence of CHD? *Public Health Nutr.* 2013;16:2055–63.
119. Goldbohm RA, Chorus AM, Galindo Garre F, Schouten LJ, van den Brandt PA. Dairy consumption and 10-y total and cardiovascular mortality: a prospective cohort study in The Netherlands. *Am J Clin Nutr.* 2011;93:615–27.
120. Aslibekyan S, Campos H, Baylin A. Biomarkers of dairy intake and the risk of heart disease. *Nutr Metab Cardiovasc Dis.* 2012;22:1039–45.
121. Patterson E, Larsson SC, Wolk A, Akesson A. Association between dairy food consumption and risk of myocardial infarction in women differs by type of dairy food. *J Nutr.* 2013;143:74–9.
122. Sonestedt E, Wirfalt E, Wallstrom P, Gullberg B, Orho-Melander M, Hedblad B. Dairy products and its association with incidence of cardiovascular disease: the Malmo Diet and Cancer Cohort. *Eur J Epidemiol.* 2011;26:609–18.
123. Soedamah-Muthu SS, Ding EL, Al-Delaimy WK, Hu FB, Engberink MF, Willett WC, Geleijnse JM. Milk and dairy consumption and incidence of cardiovascular diseases and all-cause mortality: dose-response meta-analysis of prospective cohort studies. *Am J Clin Nutr.* 2011;93:158–71.
124. van Aerde MA, Soedamah-Muthu SS, Geleijnse JM, Snijder MB, Nijpels G, Stehouwer CD, Dekker JM. Dairy intake in relation to cardiovascular disease mortality and all-cause mortality: the Hoorn Study. *Eur J Nutr.* 2013;52:609–16.
125. Razanamahefa L, Lafay L, Oseredczuk M, Thiebaut A, Laloux L, Gerber M, Astorg P, Berta JL. [Dietary fat consumption of the French population and quality of the data on the composition of the major food groups.] *Bull Cancer.* 2005;92:647–57.
126. Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox". *Semin Thromb Hemost.* 2010;36:59–70.
127. Wu JM, Hsieh TC. Resveratrol: a cardioprotective substance. *Ann N Y Acad Sci.* 2011;1215:16–21.
128. Poli A, Marangoni F, Avogaro A, Barba G, Bellentani S, Bucci M, Cambieri R, Catapano AL, Costanzo S, Cricelli C, et al. Moderate alcohol use and health: a consensus paper. *Nutr Metab Cardiovasc Dis.* 2013;23:487–504.
129. Drewnowski A, Henderson SA, Shore AB, Fischler C, Preziosi P, Hercberg S. Diet quality and dietary diversity in France: implications for the French paradox. *J Am Diet Assoc.* 1996;96:663–9.
130. Allès B, Samieri C, Feart C, Jutand MA, Laurin D, Barberger-Gateau P. Dietary patterns: a novel approach to examine the link between nutrition and cognitive function in older individuals. *Nutr Res Rev.* 2012;25:207–22.
131. Schaffer S, Asseburg H, Kuntz S, Muller WE, Eckert GP. Effects of polyphenols on brain ageing and Alzheimer's disease: focus on mitochondria. *Mol Neurobiol.* 2012;46:161–78.
132. Lee L, Kang SA, Lee HO, Lee BH, Park JS, Kim JH, Jung IK, Park YJ, Lee JE. Relationships between dietary intake and cognitive function level in Korean elderly people. *Public Health.* 2001;115:133–8.
133. Yamada M, Kasagi F, Sasaki H, Masunari N, Mimori Y, Suzuki G. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. *J Am Geriatr Soc.* 2003;51:410–4.
134. Rahman A, Sawyer Baker P, Allman RM, Zamrini E. Dietary factors and cognitive impairment in community-dwelling elderly. *J Nutr Health Aging.* 2007;11:49–54.
135. Crichton GE, Bryan J, Murphy KJ, Buckley J. Review of dairy consumption and cognitive performance in adults: findings and methodological issues. *Dement Geriatr Cogn Disord.* 2010;30:352–61.
136. Crichton GE, Murphy KJ, Bryan J. Dairy intake and cognitive health in middle-aged South Australians. *Asia Pac J Clin Nutr.* 2010;19:161–71.
137. Crichton GE, Elias MF, Dore GA, Abhayaratna WP, Robbins MA. Relations between dairy food intake and arterial stiffness: pulse wave velocity and pulse pressure. *Hypertension.* 2012;59:1044–51.
138. Rahmani K, Djazayeri A, Habibi MI, Heidari H, Dorosti-Motlagh AR, Pourshahriari M, Azadbakht L. Effects of daily milk supplementation on improving the physical and mental function as well as school performance among children: results from a school feeding program. *J Res Med Sci.* 2011;16:469–76.
139. Birnie K, Ben-Shlomo Y, Gunnell D, Ebrahim S, Bayer A, Gallacher J, Holly JM, Martin RM. Childhood milk consumption is associated with better physical performance in old age. *Age Ageing.* 2012;41:776–84.
140. Kampman E, Giovannucci E, van 't Veer P, Rimm E, Stampfer MJ, Colditz GA, Kok FJ, Willett WC. Calcium, vitamin D, dairy foods, and the occurrence of colorectal adenomas among men and women in two prospective studies. *Am J Epidemiol.* 1994;139:16–29.
141. Kampman E, Goldbohm RA, van den Brandt PA, van 't Veer P. Fermented dairy products, calcium, and colorectal cancer in the Netherlands Cohort Study. *Cancer Res.* 1994;54:3186–90.

142. Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Fakhrabadi-Shokoohi D, Giovannucci EL, Thun MJ, Calle EE. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. *Cancer Epidemiol Biomarkers Prev.* 2003;12:597–603.
143. Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. *Cancer Epidemiol Biomarkers Prev.* 2006;15:203–10.
144. Koh KA, Sesso HD, Paffenbarger RS Jr, Lee IM. Dairy products, calcium and prostate cancer risk. *Br J Cancer.* 2006;95:1582–5.
145. Mitrou PN, Albanes D, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, Leitzmann MF. A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). *Int J Cancer.* 2007;120:2466–73.
146. Larsson SC, Orsini N, Wolk A. Milk, milk products and lactose intake and ovarian cancer risk: a meta-analysis of epidemiological studies. *Int J Cancer.* 2006;118:431–41.
147. Cho E, Smith-Warner SA, Spiegelman D, Beeson WL, van den Brandt PA, Colditz GA, Folsom AR, Fraser GE, Freudenheim JL, Giovannucci E, et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. *J Natl Cancer Inst.* 2004;96:1015–22.
148. Nyberg F, Agrenius V, Svartengren K, Svensson C, Pershagen G. Dietary factors and risk of lung cancer in never-smokers. *Int J Cancer.* 1998;78:430–6.
149. Breslow RA, Graubard BI, Sinha R, Subar AF. Diet and lung cancer mortality: a 1987 National Health Interview Survey cohort study. *Cancer Causes Control.* 2000;11:419–31.
150. Moorman PG, Terry PD. Consumption of dairy products and the risk of breast cancer: a review of the literature. *Am J Clin Nutr.* 2004;80:5–14.
151. Park Y, Leitzmann MF, Subar AF, Hollenbeck A, Schatzkin A. Dairy food, calcium, and risk of cancer in the NIH-AARP Diet and Health Study. *Arch Intern Med.* 2009;169:391–401.
152. Norat T, Riboli E. Dairy products and colorectal cancer: a review of possible mechanisms and epidemiological evidence. *Eur J Clin Nutr.* 2003;57:1–17.
153. Giovannucci E. Dietary influences of 1,25(OH)<sub>2</sub> vitamin D in relation to prostate cancer: a hypothesis. *Cancer Causes Control.* 1998;9:567–82.
154. Pala V, Sieri S, Berrino F, Vineis P, Sacerdote C, Palli D, Masala G, Panico S, Mattiello A, Tumino R, et al. Yogurt consumption and risk of colorectal cancer in the Italian European Prospective Investigation into Cancer and Nutrition cohort. *Int J Cancer.* 2011;129:2712–9.
155. Aune D, Lau R, Chan DS, Vieira R, Greenwood DC, Kampman E, Norat T. Dairy products and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. *Ann Oncol.* 2012;23:37–45.
156. Knekt P, Jarvinen R, Seppanen R, Pukkala E, Aromaa A. Intake of dairy products and the risk of breast cancer. *Br J Cancer.* 1996;73:687–91.
157. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. *J Natl Cancer Inst.* 2002;94:1301–11.
158. Missmer SA, Smith-Warner SA, Spiegelman D, Yaun SS, Adami HO, Beeson WL, van den Brandt PA, Fraser GE, Freudenheim JL, Goldbohm RA, et al. Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies. *Int J Epidemiol.* 2002;31:78–85.
159. Dong JY, Zhang L, He K, Qin LQ. Dairy consumption and risk of breast cancer: a meta-analysis of prospective cohort studies. *Breast Cancer Res Treat.* 2011;127:23–31.
160. Terry P, Suzuki R, Hu FB, Wolk A. A prospective study of major dietary patterns and the risk of breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2001;10:1281–5.
161. Lee MM, Lin SS. Dietary fat and breast cancer. *Annu Rev Nutr.* 2000;20:221–48.
162. Mao QQ, Dai Y, Lin YW, Qin J, Xie LP, Zheng XY. Milk consumption and bladder cancer risk: a meta-analysis of published epidemiological studies. *Nutr Cancer.* 2011;63:1263–71.
163. Li F, An SL, Zhou Y, Liang ZK, Jiao ZJ, Jing YM, Wan P, Shi XJ, Tan WL. Milk and dairy consumption and risk of bladder cancer: a meta-analysis. *Urology.* 2011;78:1298–305.
164. Zhang ZF, Kurtz RC, Yu GP, Sun M, Gargon N, Karpeh M Jr, Fein JS, Harlap S. Adenocarcinomas of the esophagus and gastric cardia: the role of diet. *Nutr Cancer.* 1997;27:298–309.
165. Wolfgarten E, Rosendahl U, Nowroth T, Leers J, Metzger R, Holscher AH, Bollschweiler E. Coincidence of nutritional habits and esophageal cancer in Germany. *Onkologie.* 2001;24:546–51.
166. Chen H, Ward MH, Graubard BI, Heineman EF, Markin RM, Potischman NA, Russell RM, Weisenburger DD, Tucker KL. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. *Am J Clin Nutr.* 2002;75:137–44.
167. Levi F, Pasche C, La Vecchia C, Lucchini F, Franceschi S, Monnier P. Food groups and risk of oral and pharyngeal cancer. *Int J Cancer.* 1998;77:705–9.
168. Sánchez MJ, Martínez C, Nieto A, Castellsague X, Quintana MJ, Bosch FX, Muñoz N, Herrero R, Franceschi S. Oral and oropharyngeal cancer in Spain: Influence of dietary patterns. *Eur J Cancer Prev.* 2003;12:49–56.
169. Tseng M, Giri V, Watkins-Bruner D, Giovannucci E. Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer. *Cancer Causes Control.* 2009;20:1947–54.
170. Rohrmann S, Platz EA, Kavanaugh CJ, Thuita L, Hoffman SC, Helzlsouer KJ. Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study. *Cancer Causes Control.* 2007;18:41–50.
171. Bounous G, Batist G, Gold P. Whey proteins in cancer prevention. *Cancer Lett.* 1991;57:91–4.
172. Zivkovic AM, Barile D. Bovine milk as a source of functional oligosaccharides for improving human health. *Adv Nutr.* 2011;2:284–9.
173. Prieto PA. Profiles of human milk oligosaccharides and production of some human milk oligosaccharides in transgenic animals. *Adv Nutr.* 2012;3 Suppl:456S–64S.
174. Kuntz S, Kunz C, Rudloff S. Oligosaccharides from human milk induce growth arrest via G2/M by influencing growth-related cell cycle genes in intestinal epithelial cells. *Br J Nutr.* 2009;101:1306–15.
175. German JB, Freeman SL, Lebrilla CB, Mills DA. Human milk oligosaccharides: evolution, structures and bioselectivity as substrates for intestinal bacteria. *Nestle Nutr Workshop Ser Pediatr Program.* 2008;62:205–18; discussion 218–22.
176. Eiwegger T, Stahl B, Schmitt J, Boehm G, Gerstmayr M, Pichler J, Dehlink E, Loibichler C, Urbanek R, Szepefalusi Z. Human milk-derived oligosaccharides and plant-derived oligosaccharides stimulate cytokine production of cord blood t-cells in vitro. *Pediatr Res.* 2004;56:536–40.
177. Guggenblichler JP, De Bettignies-Dutz A, Meissner S, Jurenitsch J. Acid oligosaccharides from natural sources block adherence of *Escherichia coli* on uroepithelial cells. *Pharm Pharmacol Lett.* 1997;7:35–8.
178. Tao N, DePeters EJ, German JB, Grimm R, Lebrilla CB. Variations in bovine milk oligosaccharides during early and middle lactation stages analyzed by high-performance liquid chromatography-chip/mass spectrometry. *J Dairy Sci.* 2009;92:2991–3001.
179. Gopal PK, Gill HS. Oligosaccharides and glycoconjugates in bovine milk and colostrum. *Br J Nutr.* 2000;84 Suppl 1:S69–74.
180. Fernández L, Langa S, Martin V, Maldonado A, Jimenez E, Martin R, Rodriguez JM. The human milk microbiota: origin and potential roles in health and disease. *Pharmacol Res.* 2013;69:1–10.
181. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. *Am J Clin Nutr.* 2001;73 Suppl:399S–405S.
182. Morrow AL, Ruiz-Palacios GM, Jiang X, Newburg DS. Human-milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea. *J Nutr.* 2005;135:1304–7.
183. Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. The influence of diet on the gut microbiota. *Pharmacol Res.* 2013;69:52–60.
184. Roeselers G, Bouwman J, Venema K, Montijn R. The human gastrointestinal microbiota—an unexplored frontier for pharmaceutical discovery. *Pharmacol Res.* 2012;66:443–7.
185. Lyte M. Microbial endocrinology and nutrition: a perspective on new mechanisms by which diet can influence gut-to-brain communication. *PharmaNutrition.* 2013;1:35–9.
186. El-Sheikh MM, El-Senaity MH, Youssef YB, Shahein NM, Abd Rabou NS. Effect of ripening conditions on the proprieties of blue cheese produced from cow's and goat's milk. *J Am Sci.* 2011;7:485–90.

187. Visioli F, Rise P, Plasmati E, Pazzucconi F, Sirtori CR, Galli C. Very low intakes of n-3 fatty acids incorporated into bovine milk reduce plasma triacylglycerol and increase HDL-cholesterol concentrations in healthy subjects. *Pharmacol Res.* 2000;41:571–6.
188. Mahabir S. Methodological challenges conducting epidemiological research on nutraceuticals in health and disease. *PharmaNutrition.* 2013. Epub *ahead of print*; Available from: <http://www.sciencedirect.com/science/article/pii/S2213434413000340#FCANote>.
189. Visioli F. Pharma and nutrition: crossing the rubicon. *PharmaNutrition.* 2013;1:9.
190. Jensen RG. The composition of bovine milk lipids: January 1995 to December 2000. *J Dairy Sci.* 2002;85:295–350.
191. Fontecha J, Mayo I, Toledano G, Juarez M. Triacylglycerol composition of protected designation of origin cheeses during ripening: authenticity of milk fat. *J Dairy Sci.* 2006;89:882–7.
192. Lopez-Huertas E. Health effects of oleic acid and long chain omega-3 fatty acids (EPA and DHA) enriched milks: a review of intervention studies. *Pharmacol Res.* 2010;61:200–7.
193. Lawrence GD. Dietary fats and health: dietary recommendations in the context of scientific evidence. *Adv Nutr.* 2013;4:294–302.
194. Samelson EJ, Booth SL, Fox CS, Tucker KL, Wang TJ, Hoffmann U, Cupples LA, O'Donnell CJ, Kiel DP. Calcium intake is not associated with increased coronary artery calcification: the Framingham study. *Am J Clin Nutr.* 2012;96:1274–80.
195. Wang L, Manson JE, Sesso HD. Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials. *Am J Cardiovasc Drugs.* 2012;12:105–16.
196. Park Y, Mitrou PN, Kipnis V, Hollenbeck A, Schatzkin A, Leitzmann MF. Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study. *Am J Epidemiol.* 2007;166:1270–9.
197. Nishida C, Uauy R. WHO scientific update on health consequences of trans fatty acids: introduction. *Eur J Clin Nutr.* 2009;63 Suppl 2:S1–4.
198. Willett W, Mozaffarian D. Ruminant or industrial sources of trans fatty acids: public health issue or food label skirmish? *Am J Clin Nutr.* 2008;87:515–6.
199. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. *Aliment Pharmacol Ther.* 2008;27:104–19.
200. Contarini G, Povolito M. Phospholipids in milk fat: composition, biological and technological significance, and analytical strategies. *Int J Mol Sci.* 2013;14:2808–31.
201. Ono T, Morishita S, Murakoshi M. Novel function of bovine lactoferrin in lipid metabolism: visceral fat reduction by enteric-coated lactoferrin. *PharmaNutrition.* 2013;1:32–4.
202. Fonollá J, Lopez-Huertas E, Machado FJ, Molina D, Alvarez I, Marmol E, Navas M, Palacin E, Garcia-Valls MJ, Remon B, et al. Milk enriched with "healthy fatty acids" improves cardiovascular risk markers and nutritional status in human volunteers. *Nutrition.* 2009;25:408–14.